NewAmsterdam Pharma Company N.V.
| Security | NAMS / NewAmsterdam Pharma Company N.V. |
| Institution | CenterBook Partners LP |
| Latest Disclosed Ownership | 22,254 shares |
| Latest Disclosed Value | $ 712,351 |
CenterBook Partners LP reports 84.53% increase in ownership of NAMS / NewAmsterdam Pharma Company N.V.
On May 5, 2026 - CenterBook Partners LP filed a 13F-HR form disclosing ownership of 22,254 shares of NewAmsterdam Pharma Company N.V. (US:NAMS) valued at $712,351 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 11, 2026 disclosing 12,060 shares of NewAmsterdam Pharma Company N.V.. This represents a change in shares of 84.53% during the quarter. The current value of the position is $701,446 USD.
Institutional Ownership: 13F and NPORT Filings
The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.
Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.
Upgrade
to unlock premium data and export to Excel 
.
Disclosed Equity Positions (from 13F/NPORT Filings)
| File Date |
Effective Date | Form | Security | Class | ID | Avg Price Paid (Est) |
Reported Shares |
ΔShares | ΔShares (%) |
Reported Value (x1000) |
ΔValue (%) |
Alloc (%) |
ΔAlloc | ΔAlloc (%) | Cost Basis (x1000) |
Unrealized Gain/Loss (x1000) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-05 | 2026-03-31 | 13F | NEWAMSTERDAM PHARMA | ORDINARY SHARES | N62509109 | 22,254 | 10,194 | 84.53 | 712 | 68.32 | 0.0383 | |||||
| 2026-02-11 | 2025-12-31 | 13F | NEWAMSTERDAM PHARMA | ORDINARY SHARES | N62509109 | 12,060 | 423 | |||||||||
| 2025-11-07 | 2025-09-30 | 13F | NEWAMSTERDAM PHARMA | ORDINARY SHARES | N62509109 | 70,613 | 2,423 | 3.55 | 2,008 | 62.72 | 0.0992 | |||||
| 2025-08-12 | 2025-06-30 | 13F | NEWAMSTERDAM PHARMA | ORDINARY SHARES | N62509109 | 68,190 | -154,074 | -69.32 | 1,235 | -72.87 | 0.0686 | |||||
| 2025-05-09 | 2025-03-31 | 13F | NEWAMSTERDAM PHARMA | ORDINARY SHARES | N62509109 | 222,264 | 13,675 | 6.56 | 4,550 | -15.13 | 0.2898 | |||||
| 2025-02-13 | 2024-12-31 | 13F | NEWAMSTERDAM PHARMA | ORDINARY SHARES | N62509109 | 208,589 | 122,894 | 143.41 | 5,361 | 276.93 | 0.3202 | |||||
| 2024-11-14 | 2024-09-30 | 13F | NEWAMSTERDAM PHARMA | ORDINARY SHARES | N62509109 | 85,695 | 85,695 | 1,423 | 0.0874 |
Legend
- Shares
- The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
- Value
- The total value of the shares as of the effective date. This is provided in the filing.
- Avg. Share Price
- The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
- Class
- This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
- Allocation (%)
- The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
- Change in Allocation
- The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
- Change in Allocation (%)
- The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
- Cost Basis
- The total cost of the shares held. This is calculated as reported shares * avg. share price
- Unrealized Gain/Loss
- This is the market value of the position as of the effective date minus the cost basis.
